Zealand Pharma Submits MAA In Europe For Glepaglutide In Short Bowel Syndrome

Zealand Pharma has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for treating adult patients with short bowel syndrome (SBS). The submission is based on positive Phase 3 trial results demonstrating glepaglutide's potential to reduce or eliminate the need for parenteral support in SBS patients. Zealand Pharma also plans to initiate the EASE-5 Phase 3 trial in the second half of the year to support regulatory submission in the U.S.

Analysis

Zealand Pharma A/S (ZEAL) has achieved a significant regulatory milestone with the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, its long-acting GLP-2 analog, intended for adult patients with short bowel syndrome (SBS). This submission is underpinned by positive results from the pivotal Phase 3 EASE program, which indicated glepaglutide's potential to reduce or eliminate the need for parenteral support in these patients. The product's proposed twice-weekly subcutaneous administration via an autoinjector aims to offer a more convenient treatment regimen compared to the currently available daily GLP-2 therapy, thereby potentially reducing patient burden, as highlighted by Zealand Pharma's Chief Medical Officer. Furthermore, the company plans to initiate the EASE-5 Phase 3 trial in the second half of the year to gather additional confirmatory data supporting a future regulatory submission in the U.S., where glepaglutide has already received orphan drug designation from the FDA. This progress in Europe, coupled with a clear strategic path forward in the U.S., positions glepaglutide as a promising candidate in the SBS market, aligning with the reported 'strongly positive' sentiment surrounding this development.

Key Decisions for Investors

• Investors should closely monitor the EMA's review process for glepaglutide's MAA, as European approval would represent a major catalyst and de-risking event for Zealand Pharma, The planned initiation and subsequent results of the EASE-5 Phase 3 trial in the U.S. are critical upcoming milestones to watch, as success here could significantly expand glepaglutide's addressable market and revenue potential, Consideration should be given to glepaglutide's potential competitive advantages, notably its twice-weekly dosing regimen and its aim to reduce parenteral support dependency, which could differentiate it from existing daily SBS therapies and impact market adoption if approved.